, Volume 19, Issue 7, pp 715–728 | Cite as

A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs

  • Sherine E. Gabriel
  • Douglas Coyle
  • Larry W. Moreland
Review Article


Rheumatoid arthritis is one of the most common chronic systemic inflammatory diseases, affecting approximately 1% of the adult population. Disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of treatment for rheumatoid arthritis when combinedwith physical therapy and aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory drugs. Recently, a number of new biological therapies have been introduced for the treatment of this condition and will have a major impact on the future management of this disabling disease. In this review, we summarise data on the efficacy and tolerability of the currently available DMARDs, including gold compounds, antimalarials, penicillamine, cytotoxic drugs (azathioprine and cyclophosphamide), sulfasalazine, methotrexate, leflunomide, cyclosporin, anti-tumour necrosis factor agents, combination therapy and apheresis. A literature review and quality assessment of economic evaluations of DMARDs is presented, illustrating that there has been a paucity of economic evaluations on these agents and showing the variable quality of those studies that are available. The manuscript also addresses the pharmacoeconomic implications of the new agents for rheumatoid arthritis; the need for formal long term economic evaluations in order to determine the cost effectiveness of these costly, but highly effective, new treatments is emphasised.


  1. 1.
    Gabriel SE. Epidemiology of the rheumatic diseases. In: Harris ED, Ruddy S, Sledge CB, editors. Kelley’s textbook of rheumatology. 6th ed. Vol. 1. Philadelphia (PA): WB Saunders Company, 2000: 321–33Google Scholar
  2. 2.
    Day RO. SAARDs. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. Vol. 1. Philadelphia (PA): Mosby, 1998: 8.1–8.10Google Scholar
  3. 3.
    Furst DE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. Vol. 1. Philadelphia (PA): Mosby, 1998: 9.1–9.10Google Scholar
  4. 4.
    Moreland L, Russell A, Paulus H. Management of rheumatoid arthritis: the historical context. J Rheumatology. In pressGoogle Scholar
  5. 5.
    Forestier J. Rheumatoid arthritis and its treatment by gold salts. J Lab Clin Med 1935; 20: 837–40Google Scholar
  6. 6.
    Fraser TN. Gold therapy in rheumatoid arthritis. Ann Rheum Dis 1945; 4: 71–5PubMedCrossRefGoogle Scholar
  7. 7.
    Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: report of a multicenter controlled trial. Ann Rheum Dis 1961; 20: 315–34CrossRefGoogle Scholar
  8. 8.
    Gottlieb NL, Kiem IM, Penneys NS, et al. The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers. J Lab Clin Med 1975; 86 (6): 962–72PubMedGoogle Scholar
  9. 9.
    Highton J, Panayi GS, Shepherd P, et al. Fall in immune complex levels during gold treatment of rheumatoid arthritis. Ann Rheum Dis 1981; 40 (6): 575–9PubMedCrossRefGoogle Scholar
  10. 10.
    Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974; 80 (1): 21–6PubMedGoogle Scholar
  11. 11.
    Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis: changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum 1982; 25 (5): 540–9PubMedCrossRefGoogle Scholar
  12. 12.
    Adams CH, Cecil RL. Gold therapy in early rheumatoid arthritis. Ann Intern Med 1950; 33: 163–73PubMedGoogle Scholar
  13. 13.
    Rothermich NO, Philips VK, Bergen W, et al. Chrysotherapy: a prospective study. Arthritis Rheum 1976; 19 (6): 1321–7PubMedCrossRefGoogle Scholar
  14. 14.
    Srinivasan R, Miller BL, Paulus HE. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum 1979; 22 (2): 105–10PubMedCrossRefGoogle Scholar
  15. 15.
    Sambrook PN, Browne CD, Champion GD, et al. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol 1982; 9 (6): 932–4PubMedGoogle Scholar
  16. 16.
    Richter JA, Runge LA, Pinals RS, et al. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol 1980; 7 (2): 153–9PubMedGoogle Scholar
  17. 17.
    Epstein WV, Henke CJ, Yelin EH, et al. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis [see comments]. Ann Intern Med 1991; 114 (6): 437–44PubMedGoogle Scholar
  18. 18.
    Suarez-Almazor ME, Spooner CH, Belseck E, et al. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database of Systemic Reviews [computer file]. (2): CD002048, 2000Google Scholar
  19. 19.
    Anonymous. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study [see comments]. Am J Med 1995; 98 (2): 156–68CrossRefGoogle Scholar
  20. 20.
    Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for rheumatoid arthritis [Cochrane review]. In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software, 2000Google Scholar
  21. 21.
    Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3 (2): 103–8PubMedCrossRefGoogle Scholar
  22. 22.
    Mainland D, Sutcliffe MI. Hydroxychloroquine in rheumatoid arthritis: a six-month, double-blind trial. Bull Rheum Dis 1962; 13: 287–90Google Scholar
  23. 23.
    Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial [see comments]. Ann Intern Med 1993; 119 (11): 1067–71PubMedGoogle Scholar
  24. 24.
    Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension [see comments]. Arthritis Rheum 1999; 42 (2): 357–65PubMedCrossRefGoogle Scholar
  25. 25.
    Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 1967; 64 (2): 245–52PubMedGoogle Scholar
  26. 26.
    Reed H, Karlinsky W. Delayed onset of chloroquine retinopathy. CMAJ 1967; 97 (23): 1408–11Google Scholar
  27. 27.
    Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23 (8): 292–6PubMedGoogle Scholar
  28. 28.
    Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983; 75 (1A): 35–9PubMedCrossRefGoogle Scholar
  29. 29.
    Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12 (4): 692–4PubMedGoogle Scholar
  30. 30.
    Whisnant J, Espinosa R, Keiland R, et al. Chloroquine neuromyopathy. Mayo Clin Proc 1963; 23: 502–10Google Scholar
  31. 31.
    Ratliff NB, Estes ML, Myles JL, et al. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987; 316 (4): 191–3PubMedCrossRefGoogle Scholar
  32. 32.
    Begg T, Simpson J. Chloroquine neuromyopathy. BMJ 1964; 1: 770–2PubMedCrossRefGoogle Scholar
  33. 33.
    Loftus L. Peripheral neuropathy following chloroquine therapy. CMAJ 1963; 89: 917–20Google Scholar
  34. 34.
    McDuffie F. Bone marrow depression after drug therapy of SLE and rheumatic diseases. Ann Rheum Dis 1965; 24: 289–94PubMedCrossRefGoogle Scholar
  35. 35.
    Polano M, Cats A, Van Older G. Agranulocytosis following treatment with hydroxychloroquine. Lancet 1965; I: 1275–6CrossRefGoogle Scholar
  36. 36.
    Propp RP, Stillman JS. Agranulocytosis and hydroxychloroquine. N Engl J Med 1967; 277 (9): 492–3PubMedGoogle Scholar
  37. 37.
    Huskisson EC, Gibson TJ, Balme HW, et al. Trial comparing D-penicillamine and gold in rheumatoid arthritis: preliminary report. Ann Rheum Dis 1974; 33 (6): 532–5PubMedCrossRefGoogle Scholar
  38. 38.
    Berry H, Liyanage S, Durance R, et al. Trial comparing azathioprine and penicillamine in treatment of rheumatoid arthritis [proceedings]. Ann Rheum Dis 1976; 35 (6): 542–3PubMedCrossRefGoogle Scholar
  39. 39.
    Dixon A, Davis J, Dormandy TL, et al. Synthetic D-(-)-penicillamine in rheumatoid arthritis. Arthritis Rheum 1965; 34: 416–21Google Scholar
  40. 40.
    Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for rheumatoid arthritis [Cochrane review]. In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software, 2000Google Scholar
  41. 41.
    Levy J, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972; 15: 116–7Google Scholar
  42. 42.
    Urowitz MB, Gordon DA, Smythe HA, et al. Azathioprine in rheumatoid arthritis: a double-blind, cross over study. Arthritis Rheum 1973; 16 (3): 411–8PubMedCrossRefGoogle Scholar
  43. 43.
    Urowitz MB, Hunter T, Bookman AAM, et al. Azathioprine in rheumatoid arthritis: a double-blind study comparing full dose to half dose. J Rheumatol 1974; 1 (3): 274–81Google Scholar
  44. 44.
    Hunter T, Urowitz MB, Gordon DA, et al. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum 1975; 18 (1): 15–20PubMedCrossRefGoogle Scholar
  45. 45.
    Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol 1976; 3 (2): 140–4PubMedGoogle Scholar
  46. 46.
    De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981; 40 (6): 560–3PubMedCrossRefGoogle Scholar
  47. 47.
    Thompson PW, Kirwan JR, Barnes CG. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985; 24 (2): 167–75PubMedCrossRefGoogle Scholar
  48. 48.
    Turk JL, Parker D, Poulter LW. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 1972; 23 (4): 493–501PubMedGoogle Scholar
  49. 49.
    Lagrange PH, Mackaness GB, Miller TE. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide. J Exp Med 1974; 139 (6): 1529–39PubMedCrossRefGoogle Scholar
  50. 50.
    Kerckhaert JA, Hofhuis FM, Willers JM. Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse. Immunology 1977; 32 (6): 1027–32PubMedGoogle Scholar
  51. 51.
    Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, et al. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 1977; 145 (2): 455–9PubMedCrossRefGoogle Scholar
  52. 52.
    Ferguson RM, Simmons RL. Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors. Transplantation 1978; 25 (1): 36–8CrossRefGoogle Scholar
  53. 53.
    Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991; 34 (8): 961–72PubMedCrossRefGoogle Scholar
  54. 54.
    Currey HLF, Harris J, Mason RM, et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. BMJ 1974; 3: 763–6PubMedCrossRefGoogle Scholar
  55. 55.
    Singh G, Fries JF, Spitz P, et al. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989; 32 (7): 837–43PubMedGoogle Scholar
  56. 56.
    Paulus HE, Williams HJ, Ward JR, et al. Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis Rheum 1984; 27 (7): 721–7PubMedCrossRefGoogle Scholar
  57. 57.
    Diaz CJ, Garcia EL, Mechante T. Treatment of rheumatoid arthritis with nitrogen mustard. JAMA 1951; 147: 1418–9CrossRefGoogle Scholar
  58. 58.
    Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968; 11 (2): 151–61PubMedCrossRefGoogle Scholar
  59. 59.
    Smyth CJ, Bartholomew BA, Mills DM, et al. Cyclophosphamide therapy for rheumatoid arthritis. Arch Intern Med 1975; 135 (6): 789–93PubMedCrossRefGoogle Scholar
  60. 60.
    Williams HJ, Reading JC, Ward JR, et al. Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1980; 23 (5): 521–7PubMedCrossRefGoogle Scholar
  61. 61.
    Townes AS, Sowa JM, Shulman LE. Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 1976; 19 (3): 563–73PubMedCrossRefGoogle Scholar
  62. 62.
    Anonymous. A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 1970; 283 (17): 883–9CrossRefGoogle Scholar
  63. 63.
    Suarez-Almazor ME, Belseck E, Shea B, et al. Sulfasalazine for rheumatoid arthritis [Cochrane review]. In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software, 2000Google Scholar
  64. 64.
    van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; I (8646): 1036–8CrossRefGoogle Scholar
  65. 65.
    Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31 (6): 702–13PubMedCrossRefGoogle Scholar
  66. 66.
    Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312 (13): 818–22PubMedCrossRefGoogle Scholar
  67. 67.
    Andersen PA, West SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103 (4): 489–96PubMedGoogle Scholar
  68. 68.
    Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11 (6): 760–3PubMedGoogle Scholar
  69. 69.
    Williams HJ, Willkens RF, Samuelson Jr CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28 (7): 721–30Google Scholar
  70. 70.
    Szanto E. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety. Clin Rheumatol 1989; 8 (3): 323–30PubMedCrossRefGoogle Scholar
  71. 71.
    Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29 (7): 822–31PubMedCrossRefGoogle Scholar
  72. 72.
    Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35 (2): 138–45CrossRefGoogle Scholar
  73. 73.
    Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis [see comments]. Arthritis Rheum 1988; 31 (2): 167–75PubMedCrossRefGoogle Scholar
  74. 74.
    Weinblatt ME, Maier AL. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Reumatol 1990; 22 Suppl.: 33–8Google Scholar
  75. 75.
    Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20 (4): 639–44PubMedGoogle Scholar
  76. 76.
    Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75 (6A): 69–73PubMedCrossRefGoogle Scholar
  77. 77.
    Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992; 35 (2): 129–37PubMedCrossRefGoogle Scholar
  78. 78.
    Alarcon GS, Tracy IC, Blackburn Jr WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32 (6): 671–6PubMedCrossRefGoogle Scholar
  79. 79.
    Furst DE, Erikson N, Clute L, et al. Adverse experience with methotrexate during 176weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17 (12): 1628–35PubMedGoogle Scholar
  80. 80.
    Lopez-Mendez A, Daniel WW, Reading JC, et al. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36 (10): 1364–9PubMedCrossRefGoogle Scholar
  81. 81.
    Nordstrom DM, West SG, Andersen PA, et al. Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study. Ann Intern Med 1987; 107 (6): 797–801PubMedGoogle Scholar
  82. 82.
    Reykdal S, Steinsson K, Sigurjonsson K, et al. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989; 18 (4): 221–6PubMedCrossRefGoogle Scholar
  83. 83.
    Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of RA: results from three randomized controlled trials of leflunomide in patients with active arthritis. Arthritis Rheum 2000; 43: 495–505PubMedCrossRefGoogle Scholar
  84. 84.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159 (21): 2542–50PubMedCrossRefGoogle Scholar
  85. 85.
    Bannwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis: an update. Drugs 1994; 47 (1): 25–50PubMedCrossRefGoogle Scholar
  86. 86.
    Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis [Cochrane review]. In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software, 2000Google Scholar
  87. 87.
    Brick JE, Moreland LW, Al-Kawas F, et al. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989; 19 (1): 31–44PubMedCrossRefGoogle Scholar
  88. 88.
    Ahern MJ, Kevat S, Hill W, et al. Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings. Ann Rheum Dis 1991; 50 (7): 477–80PubMedCrossRefGoogle Scholar
  89. 89.
    Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32 (2): 121–7PubMedCrossRefGoogle Scholar
  90. 90.
    Aponte J, Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988; 31 (12): 1457–64PubMedCrossRefGoogle Scholar
  91. 91.
    Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85 (6): 771–4PubMedCrossRefGoogle Scholar
  92. 92.
    Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90 (6): 711–6PubMedCrossRefGoogle Scholar
  93. 93.
    Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29 (7): 832–5PubMedCrossRefGoogle Scholar
  94. 94.
    Bjorkman DJ, Hammond EH, Lee RG, et al. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988; 31 (12): 1465–72PubMedCrossRefGoogle Scholar
  95. 95.
    Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology [see comments]. Arthritis Rheum 1994; 37 (3): 316–28PubMedCrossRefGoogle Scholar
  96. 96.
    Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21 (1): 51–4PubMedGoogle Scholar
  97. 97.
    White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989; 139 (1): 18–21PubMedCrossRefGoogle Scholar
  98. 98.
    Ridley MG, Wolfe CS, Mathews JA. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47 (9): 784–8PubMedCrossRefGoogle Scholar
  99. 99.
    Cannon GW, Ward JR, Clegg DO, et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983; 26 (10): 1269–74PubMedCrossRefGoogle Scholar
  100. 100.
    Alarcon GS, Gispen JG, Koopman WJ. Severe reversible interstitial pneumonitis induced by low dose methotrexate [letter; comment]. J Rheumatol 1989; 16 (7): 1007–8PubMedGoogle Scholar
  101. 101.
    Engelbrecht JA, Calhoon SL, Scherrer JJ. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983; 26 (10): 1275–8PubMedCrossRefGoogle Scholar
  102. 102.
    Clarysse AM, Cathey WJ, Cartwright GE, et al. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 1969; 209 (12): 1861–8PubMedCrossRefGoogle Scholar
  103. 103.
    Landewe RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity [letter]. Lancet 2000; 355 (9215): 1616–7PubMedCrossRefGoogle Scholar
  104. 104.
    Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43 (1): 14–21PubMedCrossRefGoogle Scholar
  105. 105.
    Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol 1999; 112 Suppl.: 15–21CrossRefGoogle Scholar
  106. 106.
    Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000 Jun; 39 (6): 655–65PubMedCrossRefGoogle Scholar
  107. 107.
    Forre O, Bjerkhoel F, Salvesen CF, et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987; 30 (1): 88–92PubMedCrossRefGoogle Scholar
  108. 108.
    van Rijthoven AW, Dijkmans BA, The HS, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J Rheumatol 1991; 18 (6): 815–20PubMedGoogle Scholar
  109. 109.
    Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335 (8697): 1051–5PubMedCrossRefGoogle Scholar
  110. 110.
    Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study. Ann Intern Med 1988; 109 (11): 863–9PubMedGoogle Scholar
  111. 111.
    Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47 (2): 127–33CrossRefGoogle Scholar
  112. 112.
    van Rijthoven AW, Dijkmans BA, Goei The HS, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheumatic Dis 1986; 45 (9): 726–31CrossRefGoogle Scholar
  113. 113.
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59 (6): 1341–59PubMedCrossRefGoogle Scholar
  114. 114.
    Finck B, Martin R, Fleischmann R, et al. A phase II trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl.: S280Google Scholar
  115. 115.
    Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 26 Suppl. 57: 7–15Google Scholar
  116. 116.
    Moreland LW, Margolies G, Heck Jr LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23 (11): 1849–55PubMedGoogle Scholar
  117. 117.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N Engl J Med 1997; 337 (3): 141–7sPubMedCrossRefGoogle Scholar
  118. 118.
    Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130 (6): 478–86PubMedGoogle Scholar
  119. 119.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. N Engl J Med 1999; 340 (4): 253–9PubMedCrossRefGoogle Scholar
  120. 120.
    Lovell DJ, Giannini EH, Whitmore JB, et al. Safety and efficacy of tumor necrosis factor receptor p75 fusion protein (TNFR: Fc, Enbrel) in DMARD refractory rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 1998; 41 Suppl.: S470Google Scholar
  121. 121.
    Moreland LW, Cohen SB, Baumgartner S, et al. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl. 9: S401Google Scholar
  122. 122.
    Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group [see comments]. N Engl J Med 2000; 342 (11): 763–9PubMedCrossRefGoogle Scholar
  123. 123.
    Lipsky P, St. Clair W, Furst D, et al. Clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade) in patients with active RA despite methotrexate [abstract]. Arthritis Rheum 1999; 42 Suppl.: S1980Google Scholar
  124. 124.
    Elliott MJ, Maini RN, Feldmann M. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10PubMedCrossRefGoogle Scholar
  125. 125.
    Elliott MJ, Maini RN, Feldmann M. Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7PubMedCrossRefGoogle Scholar
  126. 126.
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41 (9): 1552–63PubMedCrossRefGoogle Scholar
  127. 127.
    Elliott MJ, Maini RN, Feldmann M. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681–90PubMedCrossRefGoogle Scholar
  128. 128.
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [see comments; published erratum appears in Lancet 1998 Jan 17; 351 (9097): 220]. Lancet 1997; 350 (9074): 309–18CrossRefGoogle Scholar
  129. 129.
    Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review [see comments]. Br J Rheumatol 1998; 37 (6): 612–9PubMedCrossRefGoogle Scholar
  130. 130.
    Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131 (10): 768–74PubMedGoogle Scholar
  131. 131.
    Boers M, Ramsden M. Long acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18 (3): 316–24PubMedGoogle Scholar
  132. 132.
    Tugwell P. Long-acting drug combinations in rheumatoid arthritis: a formal overview. In: Wolfe F, Pincus T, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome, and treatment. Updated overview. New York (NY): Marcel Dekker, 1994: 347–71Google Scholar
  133. 133.
    Felson DT, LaValley MP, Baldassare AR, et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999; 42 (10): 2153–9PubMedCrossRefGoogle Scholar
  134. 134.
    Making cost-effectiveness information accessible: the NHS economic evaluation database project. CRD Guidance for reporting critical summaries of economic evaluations. York: NHS Centre for Reviews and Disseminations, University of York, 1996. CRD Report No. 6Google Scholar
  135. 135.
    Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997Google Scholar
  136. 136.
    Rothfuss J, Mau W, Zeidler H, et al. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997; 26 (5): 771–9PubMedCrossRefGoogle Scholar
  137. 137.
    Maetzel A, Ferraz MB, Bombardier C. A review of cost-effectiveness analyses in rheumatology and related disciplines. Curr Opin Rheumatol 1998; 10 (2): 136–40PubMedCrossRefGoogle Scholar
  138. 138.
    Ferraz MB, Maetzel A, Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis Rheum 1997; 40 (9): 1587–93PubMedCrossRefGoogle Scholar
  139. 139.
    Thompson MS, Read JL, Hutchings HC, et al. The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988; 15 (1): 35–42PubMedGoogle Scholar
  140. 140.
    Anis AH, Tugwell PX, Wells GA, et al. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996; 23: 609–16PubMedGoogle Scholar
  141. 141.
    Verhoeven AC, Bibo JC, Boers M, et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down presalazine alone. Br J Rheumatol 1998; 37 (10): 1102–9PubMedCrossRefGoogle Scholar
  142. 142.
    Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 1995; 38 (3): 318–25PubMedCrossRefGoogle Scholar
  143. 143.
    Kavanaugh A, Heudebert G, Cush J, et al. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25 (5): 297–307PubMedCrossRefGoogle Scholar
  144. 144.
    Borg G, Allander E, Goobar JE. Disease-modifying anti-rheumatic drug therapy: an expensive therapy despite inexpensive drugs. Scand J Rheumatol 1990; 19 (2): 115–21PubMedCrossRefGoogle Scholar
  145. 145.
    Fries JF. ARAMIS and toxicity measurement (Arthritis Rheumatism and Aging Medical Information System). J Rheumatol 1995; 22: 995–7PubMedGoogle Scholar
  146. 146.
    Kaplan RM, Anderson JP, Wu AW, et al. The quality of well-being scale: applications inAIDS, cystic fibrosis and arthritis. Medical Care 1989; 27: S27–43PubMedCrossRefGoogle Scholar
  147. 147.
    Torrance GW, Feeny D. Utilities and quality adjusted life years. Int J Technol Assess Health Care 1989; 5: 559–75PubMedCrossRefGoogle Scholar
  148. 148.
    Gabriel SE, Drummond MF, Coyle D, et al. OMERACT 5 — economics working group: summary, recommendations, and research agenda. J Rheumatol 2001; 28: 670–3PubMedGoogle Scholar
  149. 149.
    Coyle D, Welch V, Shea B, et al. Issues of consensus and debate for economic evaluation in rheumatology. J Rheumatol 2001; 28: 642–7PubMedGoogle Scholar
  150. 150.
    Gabriel SE, Crowson CS, Luthra HS, et al. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26 (6): 1269–74PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Sherine E. Gabriel
    • 1
  • Douglas Coyle
    • 2
  • Larry W. Moreland
    • 3
  1. 1.Health Sciences ResearchMayo FoundationRochesterUSA
  2. 2.Clinical Epidemiology Unit, Loeb Research InstituteOttawa HospitalOttawaCanada
  3. 3.Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations